Literature DB >> 24623627

Adenovirus type 4 and 7 vaccination or adenovirus type 4 respiratory infection elicits minimal cross-reactive antibody responses to nonhuman adenovirus vaccine vectors.

Robert Paris1, Robert A Kuschner, Leonard Binn, Stephen J Thomas, Stefano Colloca, Alfredo Nicosia, Riccardo Cortese, Robert T Bailer, Nancy Sullivan, Richard A Koup.   

Abstract

Antivector immunity may limit the immunogenicity of adenovirus vector vaccines. We tested sera from individuals immunized with adenovirus type 4 and 7 (Ad4 and Ad7, respectively) vaccine or naturally infected with Ad4 for their ability to neutralize a panel of E1-deleted human and chimpanzee adenoviruses (ChAd). Small statistically significant increases in titers to ChAd63, ChAd3, human Ad35, and human Ad5 were observed. Neutralizing antibodies elicited by Ad4 infection or immunization results in a small amount of adenovirus cross-reactivity.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24623627      PMCID： PMC4018874          DOI： 10.1128/CVI.00011-14

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  26 in total

1.  Neutralizing and complement fixing antibody response to adenovirus infection.

Authors:  J T GRAYSTON; P B JOHNSTON; C G LOOSLI; M E SMITH; R L WOOLRIDGE
Journal:  J Infect Dis       Date:  1956 Sep-Oct       Impact factor: 5.226

Review 2.  Adenovirus vector-based vaccines for human immunodeficiency virus type 1.

Authors:  Dan H Barouch; Gary J Nabel
Journal:  Hum Gene Ther       Date:  2005-02       Impact factor: 5.695

Review 3.  Production and formulation of adenovirus vectors.

Authors:  Nedim E Altaras; John G Aunins; Robert K Evans; Amine Kamen; John O Konz; Jayanthi J Wolf
Journal:  Adv Biochem Eng Biotechnol       Date:  2005       Impact factor: 2.635

4.  A double-blind, placebo-controlled study of the safety and immunogenicity of live, oral type 4 and type 7 adenovirus vaccines in adults.

Authors:  Arthur Lyons; Jenice Longfield; Robert Kuschner; Timothy Straight; Leonard Binn; Jitvimol Seriwatana; Raven Reitstetter; Irma B Froh; David Craft; Kevin McNabb; Kevin Russell; David Metzgar; Alan Liss; Xiao Sun; Andrew Towle; Wellington Sun
Journal:  Vaccine       Date:  2008-04-10       Impact factor: 3.641

5.  Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector.

Authors:  Andrew T Catanzaro; Richard A Koup; Mario Roederer; Robert T Bailer; Mary E Enama; Zoe Moodie; Lin Gu; Julie E Martin; Laura Novik; Bimal K Chakrabarti; Bryan T Butman; Jason G D Gall; C Richter King; Charla A Andrews; Rebecca Sheets; Phillip L Gomez; John R Mascola; Gary J Nabel; Barney S Graham
Journal:  J Infect Dis       Date:  2006-11-08       Impact factor: 5.226

6.  Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults.

Authors:  Frances H Priddy; Deborah Brown; James Kublin; Kathleen Monahan; David P Wright; Jacob Lalezari; Steven Santiago; Michael Marmor; Michelle Lally; Richard M Novak; Stephen J Brown; Priya Kulkarni; Sheri A Dubey; Lisa S Kierstead; Danilo R Casimiro; Robin Mogg; Mark J DiNubile; John W Shiver; Randi Y Leavitt; Michael N Robertson; Devan V Mehrotra; Erin Quirk
Journal:  Clin Infect Dis       Date:  2008-06-01       Impact factor: 9.079

7.  HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis.

Authors:  M Juliana McElrath; Stephen C De Rosa; Zoe Moodie; Sheri Dubey; Lisa Kierstead; Holly Janes; Olivier D Defawe; Donald K Carter; John Hural; Rama Akondy; Susan P Buchbinder; Michael N Robertson; Devan V Mehrotra; Steven G Self; Lawrence Corey; John W Shiver; Danilo R Casimiro
Journal:  Lancet       Date:  2008-11-13       Impact factor: 79.321

8.  Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.

Authors:  Susan P Buchbinder; Devan V Mehrotra; Ann Duerr; Daniel W Fitzgerald; Robin Mogg; David Li; Peter B Gilbert; Javier R Lama; Michael Marmor; Carlos Del Rio; M Juliana McElrath; Danilo R Casimiro; Keith M Gottesdiener; Jeffrey A Chodakewitz; Lawrence Corey; Michael N Robertson
Journal:  Lancet       Date:  2008-11-13       Impact factor: 79.321

9.  Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors.

Authors:  Kimberly McCoy; Nia Tatsis; Birgit Korioth-Schmitz; Marcio O Lasaro; Scott E Hensley; Shih-Wen Lin; Yan Li; Wynetta Giles-Davis; Ann Cun; Dongming Zhou; Zhiquan Xiang; Norman L Letvin; Hildegund C J Ertl
Journal:  J Virol       Date:  2007-04-11       Impact factor: 5.103

10.  Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy.

Authors:  M Dudareva; L Andrews; S C Gilbert; P Bejon; K Marsh; J Mwacharo; O Kai; A Nicosia; A V S Hill
Journal:  Vaccine       Date:  2009-04-16       Impact factor: 3.641
View more
  10 in total

Review 1.  Viral Infections and Obesity.

Authors:  Jameson D Voss; Nikhil V Dhurandhar
Journal:  Curr Obes Rep       Date:  2017-03

2.  Neutralizing antibodies against adenovirus type 2 in normal and HIV-1-infected subjects: Implications for use of Ad2 vectors in vaccines.

Authors:  Qianqian Li; Qiang Liu; Weijing Huang; Aijing Song; Chenyan Zhao; Jiajing Wu; Youchun Wang
Journal:  Hum Vaccin Immunother       Date:  2017-03-16       Impact factor: 3.452

3.  Encapsulation of Adenovirus BMP2-Transduced Cells with PEGDA Hydrogels Allows Bone Formation in the Presence of Immune Response.

Authors:  Pedro Alvarez-Urena; Eleanor Davis; Corinne Sonnet; Gabrielle Henslee; Zbigniew Gugala; Edward V Strecker; Laura J Linscheid; Maude Cuchiara; Jennifer West; Alan Davis; Elizabeth Olmsted-Davis
Journal:  Tissue Eng Part A       Date:  2017-01-25       Impact factor: 3.845

4.  Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinant Ad5-HIV vaccinated individuals.

Authors:  Haitao Hu; Michael A Eller; Shah Zafar; Yu Zhou; Mengnan Gu; Zhi Wei; Jeffrey R Currier; Mary A Marovich; Hannah N Kibuuka; Robert T Bailer; Richard A Koup; Merlin L Robb; Nelson L Michael; Jerome H Kim; Silvia Ratto-Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-02       Impact factor: 11.205

Review 5.  Vector-based genetically modified vaccines: Exploiting Jenner's legacy.

Authors:  Bahar Ramezanpour; Ingrid Haan; Ab Osterhaus; Eric Claassen
Journal:  Vaccine       Date:  2016-10-28       Impact factor: 3.641

6.  Nonhuman Primate Adenoviruses of the Human Adenovirus B Species Are Potent and Broadly Acting Oncolytic Vector Candidates.

Authors:  Selas T F Bots; Vera Kemp; Steve J Cramer; Diana J M van den Wollenberg; Marten Hornsveld; Martine L M Lamfers; Gabri van der Pluijm; Rob C Hoeben
Journal:  Hum Gene Ther       Date:  2022-03       Impact factor: 5.695

7.  Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial.

Authors:  Emma-Jo Hayton; Annie Rose; Umar Ibrahimsa; Mariarosaria Del Sorbo; Stefania Capone; Alison Crook; Antony P Black; Lucy Dorrell; Tomáš Hanke
Journal:  PLoS One       Date:  2014-07-09       Impact factor: 3.240

8.  Challenges, progress, and opportunities: proceedings of the filovirus medical countermeasures workshop.

Authors:  Rona Hirschberg; Lucy A Ward; Nicole Kilgore; Rebecca Kurnat; Helen Schiltz; Mark T Albrecht; George W Christopher; Ed Nuzum
Journal:  Viruses       Date:  2014-07-09       Impact factor: 5.048

9.  Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial.

Authors:  Milagritos D Tapia; Samba O Sow; Kirsten E Lyke; Fadima Cheick Haidara; Fatoumata Diallo; Moussa Doumbia; Awa Traore; Flanon Coulibaly; Mamoudou Kodio; Uma Onwuchekwa; Marcelo B Sztein; Rezwanul Wahid; James D Campbell; Marie-Paule Kieny; Vasee Moorthy; Egeruan B Imoukhuede; Tommy Rampling; Francois Roman; Iris De Ryck; Abbie R Bellamy; Len Dally; Olivier Tshiani Mbaya; Aurélie Ploquin; Yan Zhou; Daphne A Stanley; Robert Bailer; Richard A Koup; Mario Roederer; Julie Ledgerwood; Adrian V S Hill; W Ripley Ballou; Nancy Sullivan; Barney Graham; Myron M Levine
Journal:  Lancet Infect Dis       Date:  2015-11-04       Impact factor: 25.071

Review 10.  Non-Human Primate-Derived Adenoviruses for Future Use as Oncolytic Agents?

Authors:  Selas T F Bots; Rob C Hoeben
Journal:  Int J Mol Sci       Date:  2020-07-08       Impact factor: 5.923
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.